Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Biliary Tract Neoplasms 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 6Biopsy 6Doxorubicin 5pembrolizumab 4X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Cyclophosphamide 4liposomal doxorubicin 3fludarabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine phosphate 2ensartinib 2atezolizumab 2anlotinib 2Temozolomide 2Radiation 2Irinotecan 2Ifosfamide 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × envafolimab × 30 days × Clear all
NCT05941325 2026-06-05

A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma

Shanghai 6th People's Hospital

Phase 2 Suspended
20 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡